44 completed, 33 recruiting, 11 terminated, 9 active not recruiting. 123 Phase 1, 42 Phase 2.
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Budesonide delayed release tablet - IgA Nephropathy | Phase 1 | Not yet recruiting | Triastek, lnc. | 18 | 2026-10-01 | 2026-10-27 |
| CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo | 16 | 2026-10-01 | 2026-10-29 |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| US Zamto-cel Autoimmune Diseases zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Miltenyi Biomedicine GmbH | 48 | 2026-07-01 | 2026-06-11 |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus | Phase 1 | Withdrawn | Genentech, Inc. | 2026-06-30 | 2026-08-05 | |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| PS-002 for the Treatment of IgA Nephropathy in Adults PS-002 - Immunoglobulin A (IgA) Nephropathy | Phase 1 / Phase 2 | Recruiting | Purespring Therapeutics Limited | 32 | 2026-03-30 | 2026-09-09 |
| A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) HB2198 - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | Hinge Bio | 30 | 2026-03-23 | 2026-03-25 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment RG002C0106 - Renal Impairments, IgA Nephropathy (IgAN) | Phase 1 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 24 | 2026-03-15 | 2026-10-15 |
| SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide - REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 24 | 2026-03-02 | 2026-04-13 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Vonsetamig, Odronextamab - Lupus Nephritis (LN) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2025-12-22 | 2026-10-27 |
| Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment. - Refractory Membranous Nephropathy | Phase 1 | Recruiting | The First Affiliated Hospital of Air Force Medicial University | 5 | 2025-12-08 | 2025-12-24 |
Showing 20 of 123. Sign in to see all of them.
Lupus Nephritis (71) · Lupus Erythematosus, Systemic (46) · Glomerulonephritis, IGA (23) · Autoimmune Diseases (20) · Scleroderma, Systemic (18) · Glomerulosclerosis, Focal Segmental (16) · Myositis (13) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (12) · Glomerulonephritis, Membranous (8) · Scleroderma, Diffuse (7) · Glomerulonephritis, Membranoproliferative (6) · Kidney Diseases (6) · Proteinuria (6) · Dermatomyositis (5)
Female Urogenital Diseases (123) · Female Urogenital Diseases and Pregnancy Complications (123) · Male Urogenital Diseases (123) · Urogenital Diseases (123) · Urologic Diseases (121) · Nephritis (119) · Kidney Diseases (117) · Immune System Diseases (104) · Autoimmune Diseases (81) · Skin and Connective Tissue Diseases (74) · Connective Tissue Diseases (72) · Lupus Erythematosus, Systemic (26) · Skin Diseases (25) · Nervous System Diseases (18)
Cyclophosphamide (21) · fludarabine (16) · Rituximab (4) · Adrenocorticotropic Hormone (2) · Galactose (2) · apixaban (2) · dapagliflozin (2) · felzartamab (2) · fludarabine phosphate (2) · Abatacept (1) · Adalimumab (1) · Bendamustine Hydrochloride (1) · Bone Marrow Purging (1) · Budesonide (1) · CTL019 chimeric antigen receptor (1)
China Immunotech (Beijing) Biotechnology Co., Ltd. (4) · Beijing GoBroad Hospital (3) · Northwell Health (3) · Takeda (3) · Ain Shams University (2) · Arrowhead Pharmaceuticals (2) · Beijing Mabworks Biotech Co., Ltd. (2) · Bristol-Myers Squibb (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · HI-Bio, A Biogen Company (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Kyverna Therapeutics (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · University of Iowa (2)
United States (63) · China (32) · Australia (14) · Germany (10) · United Kingdom (10) · South Korea (9) · Spain (9) · Canada (8) · France (7) · Poland (5) · Brazil (4) · Italy (4) · Taiwan (3) · Belgium (2) · Czechia (2)
Howard Trachtman, MD (3) · Richard JH Smith, MD (2) · Alberto Ortiz Arduan (1) · Alice Bertaina, MD (1) · Anca D Askanase, MD, MPH (1) · Betty Diamond, MD (1) · Bryan Curtis, M.D. (1)
PMID 34778952, PMID 38299639, PMID 40465397, PMID 15807196, PMID 21356124, PMID 22403278, PMID 30428931, PMID 35224732, PMID 35412950, PMID 35570983, PMID 35692547, PMID 37528520, PMID 38334499, PMID 39015674, PMID 39186380, PMID 39356039, PMID 40297949, PMID 40337980, PMID 40378845, PMID 40444214, PMID 40478760, PMID 40482854, PMID 40936477, PMID 41333097, PMID 41805697, PMID 42001190, PMID 42275148
2023 (2), 2025 (2), 2014 (1), 2018 (1)